Navigation Links
Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
Date:7/25/2012

FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated for the treatment of venous leg ulcers.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

The Phase 2b trial was designed to determine the potential effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection and skin irritation.  The safety profile of the active groups was similar to the vehicle control.

The 24-week open-label extension of this Phase 2b trial was designed to evaluate the status of the target wound (e.g., open, re-opened or healed), as well as the status of the periwound area following the 12-week treatment period. HP802-247 was not administered to patients durin
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
2. Robert Farrell Joins Bionovos Board of Directors
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
11. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Moerae Matrix Inc. announced today the initiation ... MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 ... characterized by inflammation and fibrosis.  The study, conducted ... is a double-blind, two-way cross-over design lipopolysaccharide (LPS) ... of MMI-0100 when given via inhalation to healthy ...
(Date:7/28/2015)... 28, 2015 CSL Behring announced ... accepted for review the company,s Biologics License Application (BLA) ... for the treatment of hemophilia A. In the pivotal ... Hemophilia A is a congenital bleeding ... all affected patients are male. People with hemophilia A ...
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... (Nasdaq: ONXX ) today announced that it ... January 30, at 8:30,a.m. Eastern Time. Interested parties ... http://www.wsw.com/webcast/wa48/onxx/ , It is recommended ... order to,register and download any necessary software. For ...
... Inc.,(NYSE: FRX ), Forest Laboratories Holdings, Ltd., ... GmbH announced that they have filed a second,lawsuit ... of Delaware against,additional companies for infringement of U.S. ... Forest,s Namenda(R) product. The defendants,named in the lawsuit ...
... CENTREVILLE, Va., Jan. 25 Octapharma is ... member of the Biotechnology Industry,Organization. Membership in ... is the Association,s considerable influence on the ... some of the,largest and most research intensive ...
Cached Biology Technology:Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2Octapharma Joins Biotechnology Industry Organization 2
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... R.I. [Brown University] Any parent knows that newborns still ... fully acute vision. In a wide variety of nascent animals, ... then leave it to the developing nervous system to do ... provide new evidence of a role for exposure to light ...
... of the story of muscle development, Johns Hopkins researchers ... builds finger-like projections that invade into another muscle cell,s ... muscle cell fusion, the researchers say, is not only ... regeneration after injury or disease. The work, they believe, ...
... based in the Faculty of Medicine & Dentistry at ... handed out by the Canadian Society of Chemistry for ... Li and Jonathan Martin, faculty members of the Division ... Laboratory Medicine & Pathology, have all been recognized by ...
Cached Biology News:Early light refines the brain's circuitry for vision 2Early light refines the brain's circuitry for vision 3Early light refines the brain's circuitry for vision 4How muscle develops: A dance of cellular skeletons 2How muscle develops: A dance of cellular skeletons 3U of Alberta research group recognized with national chemistry awards 2
WTAP Antibody...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Biology Products: